Boehringer Ingelheim outlines new Pradaxa research plans

Boehringer Ingelheim has reported key clinical milestones for its successful oral anticoagulant product Pradaxa, while outlining its plans for further studies.

The drug has accrued more than two million patient-years of experience in all licensed indications globally, with 12 company-sponsored trials of the compound currently in progress.

Plans are now being made to gather real-world evidence supporting Pradaxa's efficacy in patients with non-valvular atrial fibrillation, while data on the drug is being collected for use in the Gloria-AF Registry Programme.

This will help to further reinforce Pradaxa's status as the longest-studied novel oral anticoagulant on the market.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "We are building upon Pradaxa's strong foundation in clinical research and prescribing experience to deepen our understanding of the treatment's benefit/risk profile to address evolving patient needs."

This comes in the same week that the company is sharing the latest information on Pradaxa at the European Society of Cardiology Congress in Amsterdam.